Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017–1029.
   PubMed Web of Science ®Google Scholar
• Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011;29:544–550.
   PubMed Web of Science ®Google Scholar
• Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011;25:1–9.
   PubMed Web of Science ®Google Scholar
• Rao VA, Plunkett W. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine. Clin Cancer Res 2003;9:3204–3212.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Chuang EY, Davis RE, . Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428–1434.
   PubMed Web of Science ®Google Scholar
• Gandhi V. p53 as a predictor for chemotherapy response in CLL cells. Leuk Lymphoma 2007;48:219–220.
   PubMed Web of Science ®Google Scholar
• Zenz T, Benner A, Dohner H, . Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008;7:3810–3814.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mohr J, Edelmann J, . Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009;50:510–513.
   PubMed Web of Science ®Google Scholar
• Zenz T, Frohling S, Mertens D, . Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:71–84.
   PubMed Web of Science ®Google Scholar
• Sturm I, Bosanquet AG, Hermann S, . Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003;10:477–484.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Sander S, Bullinger L, . Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242–1245.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:481–488.
   PubMedGoogle Scholar
• Zenz T, Mertens D, Kuppers R, . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37–50.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Gryshchenko I, Hofbauer S, Stoecher M, . MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008;26:2252–2257.
   PubMed Web of Science ®Google Scholar
• Zenz T, Habe S, Denzel T, . Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589–2597.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mohr J, Eldering E, . miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009;113:3801–3808.
   PubMed Web of Science ®Google Scholar
• Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225–231.
   PubMed Web of Science ®Google Scholar
• Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155–168.
   PubMed Web of Science ®Google Scholar
• Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609–622.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li B. Mdm2 links genotoxic stress and metabolism to p53. Protein Cell 2010;1:1063–1072.
   PubMedGoogle Scholar
• Bommer GT, Gerin I, Feng Y, . p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298–1307.
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, . Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402–412.
   PubMed Web of Science ®Google Scholar
• Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010;2:a000935.
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang C, Wu R, . Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 2011;3:44–50.
   PubMed Web of Science ®Google Scholar
• Liang Y, Lin SY, Brunicardi FC, . DNA damage response pathways in tumor suppression and cancer treatment. World J Surg 2009;33:661–666.
   PubMed Web of Science ®Google Scholar
• Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009;9:714–723.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011;2011:603925.
   Google Scholar
• Wattel E, Preudhomme C, Hecquet B, . p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148–3157.
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, . p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580–1589.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Malcikova J, Smardova J, Rocnova L, . Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009;114:5307–5314.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Dohner H, . Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011;25:131–137.
   PubMed Web of Science ®Google Scholar
• Zenz T, Krober A, Scherer K, . Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322–3329.
   PubMed Web of Science ®Google Scholar
• Dicker F, Herholz H, Schnittger S, . The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117–124.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Deambrogi C, . The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995–1004.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, . TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473–4479.
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Martinez P, Wade R, . Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223–2229.
   PubMed Web of Science ®Google Scholar
• Saddler C, Ouillette P, Kujawski L, . Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008;111:1584–1593.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW, . Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799–804.
   PubMed Web of Science ®Google Scholar
• Turgut B, Vural O, Pala FS, . 17p deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma 2007;48:311–320.
   PubMed Web of Science ®Google Scholar
• Trbusek M, Smardova J, Malcikova J, . Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703–2708.
   PubMed Web of Science ®Google Scholar
• Fegan C, Robinson H, Thompson P, . Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995;9:2003–2008.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, . 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516–2522.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Stewart GS, Fegan C, . Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002;99:300–309.
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, . Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448–5457.
   PubMed Web of Science ®Google Scholar
• Austen B, Powell JE, Alvi A, . Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175–3182.
   PubMed Web of Science ®Google Scholar
• Cejkova S, Rocnova L, Potesil D, . Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. Eur J Haematol 2009;82:133–142.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Tam C, Abruzzo LV, . Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373–380.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, . Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994–4001.
   PubMed Web of Science ®Google Scholar
• Valganon M, Giraldo P, Agirre X, . p53 aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol 2005;129:53–59.
   PubMed Web of Science ®Google Scholar
• Konikova E, Kusenda J. Altered expression of p53 and MDM2 proteins in hematological malignancies. Neoplasma 2003;50:31–40.
   PubMed Web of Science ®Google Scholar
• Baran-Marszak F, Feuillard J, Najjar I, . Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood 2004;104:2475–2483.
   PubMed Web of Science ®Google Scholar
• Romanov VV, James CH, Sherrington PD, . Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia. Oncogene 2005;24:6855–6860.
   PubMed Web of Science ®Google Scholar
• Willander K, Ungerback J, Karlsson K, . MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. Eur J Haematol 2010;85:251–256.
   PubMed Web of Science ®Google Scholar
• Asslaber D, Pinon JD, Seyfried I, . microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 2010;115:4191–4197.
   PubMed Web of Science ®Google Scholar
• Merkel O, Asslaber D, Pinon JD, . Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle 2010;9:2764–2768.
   PubMed Web of Science ®Google Scholar
• Chang TC, Wentzel EA, Kent OA, . Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745–752.
   PubMed Web of Science ®Google Scholar
• Tarasov V, Jung P, Verdoodt B, . Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586–1593.
   PubMed Web of Science ®Google Scholar
• Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008;105:13421–13426.
   PubMed Web of Science ®Google Scholar
• Jones GG, Carter A, Pettitt AR, . The arginine-encoding variant of the p21 (CDKN1A, p21WAF, Cip1) codon 31 polymorphism is over-represented in patients with CLL and is associated with failure of p21 induction following irradiation. Leuk Lymphoma 2005;46 (Suppl. 1):S56.
   Google Scholar
• Johnson GG, Sherrington PD, Carter A, . A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res 2009;69:5210–5217.
   PubMed Web of Science ®Google Scholar
• Lee JY, Yu SJ, Park YG, . Glycogen synthase kinase 3beta phosphorylates p21WAF1/CIP1 for proteasomal degradation after UV irradiation. Mol Cell Biol 2007;27:3187–3198.
   PubMed Web of Science ®Google Scholar
• Bastin-Coyette L, Cardoen S, Smal C, . Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines. Biochem Pharmacol 2011;81:586–593.
   PubMed Web of Science ®Google Scholar
• Starczynski J, Pepper C, Pratt G, . Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic leukemia once treatment is initiated. J Clin Oncol 2005;23:1514–1521.
   PubMed Web of Science ®Google Scholar
• Syed N, Smith P, Sullivan A, . Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 2006;107:250–256.
   PubMed Web of Science ®Google Scholar
• Buggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010;34:837–842.
   PubMed Web of Science ®Google Scholar
• Iliakis G, Wang Y, Guan J, . DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003;22:5834–5847.
   PubMed Web of Science ®Google Scholar
• Heisig P. Type II topoisomerases—inhibitors, repair mechanisms and mutations. Mutagenesis 2009;24:465–469.
   PubMed Web of Science ®Google Scholar
• Rastogi RP, Richa, Kumar A, . Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair. J Nucleic Acids 2010;2010:592980.
   PubMedGoogle Scholar
• Van den Neste E, Cardoen S, Offner F, . Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Int J Oncol 2005;27:1113–1124.
   PubMed Web of Science ®Google Scholar
• Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008;27:6522–6537.
   PubMed Web of Science ®Google Scholar
• Robak T, Korycka A, Lech-Maranda E, . Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 2009;14:1183–1226.
   PubMed Web of Science ®Google Scholar
• Kojima K, Konopleva M, McQueen T, . Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006;108:993–1000.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Barbarotto E, Tiribelli M, . Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:4122–4129.
   PubMed Web of Science ®Google Scholar
• Bixby D, Kujawski L, Wang S, . The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle 2008;7:971–979.
   PubMed Web of Science ®Google Scholar
• Jones GG, Reaper PM, Pettitt AR, . The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes. Oncogene 2004;23:1911–1921.
   PubMed Web of Science ®Google Scholar
• Le Garff-Tavernier M, Blons H, Nguyen-Khac F, . Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer J 2011; 1.
   Google Scholar
• Carter A, Lin K, Sherrington PD, . Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004;127:425–428.
   PubMed Web of Science ®Google Scholar
• Carter A, Lin K, Sherrington PD, . Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia 2006;20:737–740.
   PubMed Web of Science ®Google Scholar
• Mohr J, Helfrich H, Fuge M, . DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011;117:1622–1632.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Sherrington PD, Stewart G, . p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814–822.
   PubMed Web of Science ®Google Scholar
• Mackus WJ, Kater AP, Grummels A, . Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005;19:427–434.
   PubMed Web of Science ®Google Scholar
• de Viron E, Knoops L, Connerotte T, . Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response. Br J Haematol 2009;147:641–652.
   PubMed Web of Science ®Google Scholar
• Mous R, Jaspers A, Luijks DM, . Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia 2009;23:1352–1355.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Hubank M, Cronin D, . Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 2004; 103:291–300.
   PubMed Web of Science ®Google Scholar
• Dijkstra MK, van Lom K, Tielemans D, . 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 2009;23:625–627.
   PubMed Web of Science ®Google Scholar
• Mraz M, Malinova K, Kotaskova J, . miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009;23:1159–1163.
   PubMed Web of Science ®Google Scholar
• Rossi S, Shimizu M, Barbarotto E, . microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010;116:945–952.
   PubMed Web of Science ®Google Scholar
• di Iasio MG, Addobbati R, Radillo O, . Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs 2011 May 31. [Epub ahead of print]
   Web of Science ®Google Scholar
• Best OG, Gardiner AC, Majid A, . A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008;22:1456–1459.
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Davis ZA, . A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 2009;23:212–214.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Carter A, Lenehan K, . Functional impairment of the p53 pathway detected by flow cytometry is a novel independent adverse prognostic factor in chronic lymphocytic leukaemia. Haematologica 2007;92(Suppl. 2): Abstract0910.
   Google Scholar
• Zenz T, Habe S, Denzel T, . How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance. Leukemia 2008;22:2257–2258.
   PubMed Web of Science ®Google Scholar
• Lin K, Sherrington PD, Dennis M, . Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100:1404–1409.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307–310.
   PubMed Web of Science ®Google Scholar
• Lin K, Carter A, Rockliffe N, . Functional impairment of the p53 pathway detected by flow cytometry is an independent predictor of early progression and short survival in chronic lymphocytic leukaemia (CLL). Paper presented at NCRI Cancer Conference. 7–10 November 2010. BT Convention Center, Liverpool, UK
   Google Scholar
• Pettitt AR, Sherrington PD, Cawley JC. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 1999;106:1049–1051.
   PubMed Web of Science ®Google Scholar
• Lin K, Manocha S, Harris RJ, . High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood 2003;102:1145–1146.
   PubMed Web of Science ®Google Scholar
• Willmore E, Elliott SL, Mainou-Fowler T, . DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008;14:3984–3992.
   PubMed Web of Science ®Google Scholar
• Sampath D, Calin GA, Puduvalli VK, . Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 2009;113:3744–3753.
   PubMed Web of Science ®Google Scholar